Greywolf Therapeutics

Greywolf Therapeutics is a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system.

Greywolf’s technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system, enabling the company to progress first-in-class treatments to help people living with cancers, autoimmune disorders, and infectious diseases.

Greywolf is headquartered in Oxford, UK.